Biotech Stocks News 9 October 2025

PTC Therapeutics (PTCT) Stock on November 28, 2025: S&P SmallCap 600 Debut, Insider Selling and a 90% YTD Rally

November 28, 2025 PTC Therapeutics, Inc. (NASDAQ: PTCT) is ending November 28, 2025 as one of the most talked‑about biotech small caps on Wall Street. The rare-disease specialist has just been added to several key S&P indices, is trading near

28 November 2025

PSTV Stock on November 25, 2025: FDA Meeting, Nasdaq Extension and Humana Deal Put Plus Therapeutics Back in Focus

As traders log in on Tuesday, November 25, 2025, Plus Therapeutics (NASDAQ:PSTV) is back on the radar thanks to a cluster of late‑November catalysts: an FDA Type B meeting for lead radiotherapeutic REYOBIQ™, a fresh 180‑day Nasdaq bid‑price extension, and

25 November 2025

Biotech Stocks · FDA Updates · Healthcare Deals · Nasdaq Listings · NASDAQ:PSTV · Stock Market News

KZIA Stock News Today: Kazia Therapeutics Soars on Rare Cancer Response as Nasdaq Delisting Risk Looms

Kazia Therapeutics Limited (NASDAQ: KZIA) is back on traders’ radars today after unveiling a rare immune‑complete response in a patient with metastatic triple‑negative breast cancer (TNBC) – even as the micro‑cap oncology company discloses a fresh Nasdaq delisting warning and

19 November 2025

Biotech Stocks · Cancer Research · Investment Trends · Nasdaq News · Stock Market

Cidara Therapeutics (CDTX) Surges on Accelerated Flu Drug Trial – Key Updates for Investors

Merck’s $9.2 Billion Bid Sends Cidara Therapeutics (CDTX) Soaring 105% on November 14, 2025

Cidara Therapeutics, Inc. (NASDAQ: CDTX) is at the center of Wall Street’s attention today after Merck & Co., Inc. (NYSE: MRK) agreed to acquire the San Diego–based biotech in a cash deal valued at approximately $9.2 billion, sending CDTX shares

14 November 2025

Biotech Stocks · Investment Trends · Market Analysis · Mergers & Acquisitions · NASDAQ:CDTX · NYSE:MRK · Pharma News

Viking Therapeutics (VKTX) Pops as Canaccord Nudges Price Target to $107; Stifel Conference Buzz & Fresh ObesityWeek® Data — Nov. 12, 2025

What’s new today (Nov. 12) Canaccord bumps target to $107. Before the open, Canaccord Genuity’s Edward Nash inched his VKTX target up by $1 to $107 and kept a Buy rating, framing Viking as a high‑quality obesity asset. The update

12 November 2025

Biotech Stocks · Investment Insights · Market Updates · NASDAQ:VKTX · Obesity Research · Pharma News

Axsome Therapeutics (AXSM) Skyrockets on CNS Breakthroughs: Stock Surge, Pipeline Wins, and 2025 Outlook

Stock Performance and Recent Trend Axsome’s stock has been a standout performer in 2025. As of November 3, 2025, AXSM trades around $134–$135 per share, roughly doubling from its 52-week low of $75.56 finviz.com. The stock has gained about 60%

3 November 2025

Biotech Stocks · CNS Disorders · Drug Pipeline · Investment Insights · Market Analysis · NASDAQ:AXSM

Rani Therapeutics (RANI) Stock Skyrockets ~200% on $1B Pharma Deal – Will the Rally Last?

RANI Stock Price Skyrockets on Deal News Rani’s stock price skyrocketed after the company unveiled its landmark partnership and financing news. On Friday, Oct. 17, 2025, RANI opened around $1.37 and surged as high as $2.39 intraday before settling at

20 October 2025

Biotech Stocks · Financial Analysis · Investment News · NASDAQ:RANI · Pharma Industry · Stock Market

Spruce Biosciences Skyrockets on FDA Breakthrough – Will SPRB’s Rally Last or Fade?

Spruce Biosciences (SPRB) Skyrockets 1,300% on FDA Breakthrough News – Experts Weigh In

What to Know Before Markets Open on October 20, 2025 FDA Breakthrough News Ignites Rally Spruce Biosciences’ meteoric rise began with a game-changing regulatory win. On October 6, the company announced that the FDA had granted Breakthrough Therapy Designation (BTD)

19 October 2025

Biotech Stocks · Expert Opinions · FDA News · Investment Trends · Market Analysis · NASDAQ:SPRB

Recursion (RXRX) Stock Surges on AI-Driven Breakthroughs and Big-Pharma Deals

Recursion Pharmaceuticals (NASDAQ: RXRX) is a Salt Lake City–based clinical-stage “TechBio” biotech that uses AI, automation and massive biological datasets to speed drug discovery ts2.tech. In early October 2025 the stock showed wild swings: it plunged to the mid-$5s then

16 October 2025

Artificial Intelligence · Biotech Stocks · Investment Strategies · NASDAQ:RXRX · Pharma Partnerships · Stock Market News

Theriva Biologics (TOVX) Stock Soars 92% on Oncolytic Virus Trial News – Can the Rally Last?

Recent News and Pipeline Developments Theriva Biologics (NYSE American: TOVX) has been in the news for its upcoming conference presentations and strong trial data. On October 13, 2025 the company announced that expanded data from the VIRAGE Phase 2b trial

15 October 2025

Biotech Stocks · Cancer Research · Clinical Trials · Investment Trends · Market News

Protagonist Therapeutics (PTGX) Skyrockets on J&J Buyout Buzz Amid Clinical Breakthroughs

Recent News and Corporate Developments J&J Buyout Buzz: The biggest news propelling Protagonist’s stock is the report that Johnson & Johnson is in talks to acquire Protagonist reuters.com. On October 10, 2025, The Wall Street Journal broke the story (later confirmed by Reuters) that

10 October 2025

Biotech Stocks · Clinical Trials · Investment Opportunities · Mergers & Acquisitions · NASDAQ:PTGX · Pharmaceutical Industry

Adaptimmune Stock’s Wild 2025 Ride: Speculative Surge or True Biotech Comeback?

Company Overview: Pioneering T-Cell Therapies for Cancer Adaptimmune Therapeutics plc is a UK-based biotech founded in 2008, specializing in T-cell receptor (TCR) engineered cell therapies to fight cancer ts2.tech. The company’s mission has been to “redefine how some of the

9 October 2025

Biotech Stocks · Financial News · Investment Strategies · Market Analysis · NASDAQ:ADAP · Stock Trends

Biotech Stocks News 9 October 2025 - 28 November 2025